Back to Journals » Cancer Management and Research » Volume 12

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Authors Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P

Received 6 February 2020

Accepted for publication 9 May 2020

Published 7 July 2020 Volume 2020:12 Pages 5479—5489


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly

Federica Tomao,1 Serena Maria Boccia,2 Carolina Maria Sassu,2 Martina Chirra,3 Innocenza Palaia,2 Maria Cristina Petrella,4 Violante Di Donato,2 Nicoletta Colombo,1,5 Pierluigi Benedetti Panici2

1Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; 2Department of Maternal and Child Health and Urological Sciences, “Sapienza” University of Rome,Polyclinic Umberto I, Rome, Italy; 3Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 4Medical Oncology, AOUC University Hospital Careggi, Florence, Italy; 5Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy

Correspondence: Carolina Maria Sassu
Department of Maternal and Child Health and Urological Sciences, “Sapienza” University of Rome, Polyclinic Umberto I, Viale Del Policlinico 155, Rome 00161, Italy
Tel +393935691077
Fax +390649972564

Abstract: Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.

Keywords: newly diagnosed ovarian cancer, early stage ovarian cancer, olaparib, PARPinhibitors, BRCA mutation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]